Transversus Abdominis Plane Block in the Analgesia of Acute Pancreatitis (TAPA)
Primary Purpose
Pancreatitis, Acute
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
TAP block
Conventional analgesia
Sponsored by
About this trial
This is an interventional treatment trial for Pancreatitis, Acute
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of acute pancreatitis according to modified Atlanta criteria .
- Patients with the ability to understand the VAS scale and express their level of pain.
- Patients over 18 years old.
- Uncontrolled pain, with VAS ≥ 5 after the administration of standard analgesia.
- Material and technical possibility of performing the TAP technique immediately after randomization.
- Informed consent of the participating patients for inclusion in the study.
- Informed consent of the participating patients for the administration of TAP.
- Normality of coagulation levels
Exclusion Criteria:
- Patients with American Society of Anaesthesia (ASA) levels IV and V
- Patients with chronic pancreatitis
- Pregnancy
- Patients with chronic treatment with morphic medication
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
TAP block
Conventional analgesia
Arm Description
Transversus Abdominis Plane (TAP) block technique will be carried out by a restricted group of anaesthesiologists. Standard monitoring will be applied to all patients, which will include pulse oximetry, electrocardiogram and non-invasive monitoring of blood pressure.
Patients be given conventional endovenous analgesia, and morphine 2 mg / ev every 15 minutes until the level of pain measured by a Visual Analogue Scale (VAS) ≤ 3
Outcomes
Primary Outcome Measures
Change of pain levels (VAS) after the intervention
To assess the VAS value in order to measure the time elapsed from the intervention until reaching the appropriate level of analgesic efficacy. Analgesic efficacy is defined as the patient having a pain VAS value ≤ 3.
Secondary Outcome Measures
Complications
Complications related to the analgesic technique used, either by the administration procedure or as a side effect
Full Information
NCT ID
NCT04037449
First Posted
May 27, 2019
Last Updated
November 9, 2020
Sponsor
Consorci Sanitari Integral
1. Study Identification
Unique Protocol Identification Number
NCT04037449
Brief Title
Transversus Abdominis Plane Block in the Analgesia of Acute Pancreatitis
Acronym
TAPA
Official Title
Prospective Randomized Study to Measure the Effect of Bilateral Transversus Abdominis Plane (TAP) Block in the Analgesic Control of Patients With Acute Pancreatitis (AP) and Uncontrolled Pain
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
November 30, 2020 (Anticipated)
Primary Completion Date
November 30, 2022 (Anticipated)
Study Completion Date
November 30, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Consorci Sanitari Integral
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Background Severe abdominal pain is a hallmark of acute pancreatitis (AP). A control pain is often difficult. Transversus Abdominis Plane (TAP) block has been used in pain control in patients with exacerbation of chronic pancreatitis.
Objectives To evaluate the effect of Bilateral Blockade of the Abdominal Transverse Muscle Plane (TAP Block) in the analgesic control of patients with acute pancreatitis; compared to standard intravenous analgesia.
Methods A randomized controlled trial of parallel groups will be conducted. The Study will have a multicenter development. Study population: Adult patients admitted for episode of AP, with uncontrolled pain (visual analogue scale (VAS) equal to or greater than 5 after the administration of standard analgesia. Randomization Groups: Group A: Patients who will undergo TAP block as analgesic procedure added to standard analgesia. Group B: Patients to whom morphine 2 mg / ev will be administered as analgesic procedure added to standard analgesia.
Timing of pain determination (Visual Analogue Scale, VAS):
Before conventional analgesia
Immediately before Randomization
15 minutes after the administration of the analgesic treatment object of the study.
One hour after the procedure.
Every 8 hours, during the next 4 days or until discharge of the patient.
Whenever the patient needs a dose of supplemental rescue analgesia. Analysis of data All results will be evaluated according to the initial "intention to treat". There will be a blinded assessment of the results after the last patient in the trial has completed the follow-up. The results will be presented as relative risks with their corresponding confidence intervals. P <0.05 will be considered statistically significant. In case of imbalance between the two treatment groups, a multivariate logistic regression is used to correct possible confounding factors.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatitis, Acute
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
44 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
TAP block
Arm Type
Experimental
Arm Description
Transversus Abdominis Plane (TAP) block technique will be carried out by a restricted group of anaesthesiologists. Standard monitoring will be applied to all patients, which will include pulse oximetry, electrocardiogram and non-invasive monitoring of blood pressure.
Arm Title
Conventional analgesia
Arm Type
Active Comparator
Arm Description
Patients be given conventional endovenous analgesia, and morphine 2 mg / ev every 15 minutes until the level of pain measured by a Visual Analogue Scale (VAS) ≤ 3
Intervention Type
Procedure
Intervention Name(s)
TAP block
Intervention Description
With the patient placed in the supine position, after asepsis of the skin with chlorhexidine, bilateral TAP blockage will be carried out under ultrasound control. We will use a high frequency linear transducer (12-15 MHz) on one side of the abdominal wall, at the level of the mid-axillary line, between the costal margin and the iliac crest. At this level we can identify three muscle layers, from superficial to deep: external oblique muscle, internal oblique muscle and transverse muscle of the abdomen. We will move the transducer more laterally to locate the most posterior border of the internal oblique and transverse muscles. It is at this level that we perform the posterior TAP blockade: we administer 10 ml of 2% Mepivacaine plus 10 ml of 0.5% Bupivacaine between the fasciae of the internal oblique muscle and the transverse muscle of the abdomen and observe an appropriate diffusion pattern of local anesthetics
Intervention Type
Other
Intervention Name(s)
Conventional analgesia
Intervention Description
Intravenous dexketoprofen 50 mg / 8 hours, alternate with intravenous paracetamol 1g / 8 hours. If allergy to Nonsteroidal anti-inflammatory drugs (NSAIDs) or in case of renal failure: Intravenous metamizol 2g / 8 hours alternate with intravenous paracetamol 1g / 8 hours.
Rescue Analgesia: intravenous morphine (2 mg every 15 minutes until VAS less or equal to 3)
Primary Outcome Measure Information:
Title
Change of pain levels (VAS) after the intervention
Description
To assess the VAS value in order to measure the time elapsed from the intervention until reaching the appropriate level of analgesic efficacy. Analgesic efficacy is defined as the patient having a pain VAS value ≤ 3.
Time Frame
Baseline (Before the intervention), 15 minutes after the intervention, 1 hour after the intervention, 8 hours after the intervention, 16 hours after the intervention, 24 hours after the intervention
Secondary Outcome Measure Information:
Title
Complications
Description
Complications related to the analgesic technique used, either by the administration procedure or as a side effect
Time Frame
through study completion, an average of 30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of acute pancreatitis according to modified Atlanta criteria .
Patients with the ability to understand the VAS scale and express their level of pain.
Patients over 18 years old.
Uncontrolled pain, with VAS ≥ 5 after the administration of standard analgesia.
Material and technical possibility of performing the TAP technique immediately after randomization.
Informed consent of the participating patients for inclusion in the study.
Informed consent of the participating patients for the administration of TAP.
Normality of coagulation levels
Exclusion Criteria:
Patients with American Society of Anaesthesia (ASA) levels IV and V
Patients with chronic pancreatitis
Pregnancy
Patients with chronic treatment with morphic medication
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Transversus Abdominis Plane Block in the Analgesia of Acute Pancreatitis
We'll reach out to this number within 24 hrs